Selective anterograde tracing of nonserotonergic projections from dorsal raphe nucleus to the basal forebrain and extended amygdala.
The dorsal raphe nucleus (DRN) contains both serotonergic and nonserotonergic projection neurons. Retrograde tracing studies have demonstrated that components of the basal forebrain and extended amygdala are targeted heavily by input from nonserotonergic DRN neurons. The object of this investigation was to examine the terminal distribution of nonserotonergic DRN projections in the basal forebrain and extended amygdala, using a technique that allows selective anterograde tracing of nonserotonergic DRN projections. To trace nonserotonergic DRN projections, animals were pretreated with nomifensine, desipramine and the serotonergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT), 7 days prior to placing an iontophoretic injection of biotinylated dextran amine (BDA) into the DRN. In animals treated with 5,7-DHT, numerous nonserotonergic BDA-labeled fibers ascended to the basal forebrain in the medial forebrain bundle system. Some of these labeled fibers crossed through the lateral hypothalamus, bed nucleus of the stria terminalis, and substantial innominata. These fibers entered the amygdala through the ansa peduncularis and ramified within the central and basolateral amygdaloid nuclei. Other fibers entered the diagonal band of Broca and formed a dense plexus of labeled fibers in the dorsal half of the intermediate portion of the lateral septal nucleus and the septohippocampal nucleus. These findings demonstrate that the basal forebrain and extended amygdala receive a dense projection from nonserotonergic DRN neurons. Given that the basal forebrain plays a critical role in processes such as motivation, affect, and behavioral control, these findings support the hypothesis that nonserotonergic DRN projections may exert substantial modulatory control over emotional and motivational functions.
Halberstadt
Adam L
AL
Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Balaban
Carey D
CD
D015116:5,7-Dihydroxytryptamine; D018759:Adrenergic Uptake Inhibitors; D000679:Amygdala / Q000166:cytology* / Q000378:metabolism; D000818:Animals; D001369:Axons / Q000378:metabolism / Q000648:ultrastructure; D001710:Biotin / Q000031:analogs & derivatives; D001931:Brain Mapping / Q000379:methods; D003891:Desipramine; D003911:Dextrans; D018765:Dopamine Uptake Inhibitors; D004525:Efferent Pathways / Q000166:cytology / Q000378:metabolism; D008297:Male; D008474:Medial Forebrain Bundle / Q000166:cytology / Q000378:metabolism; D008636:Mesencephalon / Q000166:cytology* / Q000378:metabolism; D009498:Neurotoxins; D018377:Neurotransmitter Agents / Q000032:analysis*; D009627:Nomifensine; D011903:Raphe Nuclei / Q000166:cytology* / Q000378:metabolism; D051381:Rats; D020318:Rats, Long-Evans; D012686:Septal Nuclei / Q000166:cytology* / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods; D013377:Substantia Innominata / Q000166:cytology / Q000378:metabolism
D018759:Adrenergic Uptake Inhibitors; D003911:Dextrans; D018765:Dopamine Uptake Inhibitors; D009498:Neurotoxins; D018377:Neurotransmitter Agents; C076397:biotinylated dextran amine; D009627:Nomifensine; D015116:5,7-Dihydroxytryptamine; D001710:Biotin; D003891:Desipramine